Brisbane, CA, December 21, 2020 – FlemingMartin is pleased to announce that Myovant Sciences (NYSE: MYOV), a biopharmaceutical company focused on redefining care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, has hired Frank Forney as their Vice President, FP&A.
Frank brings nearly two decades of financial leadership and biopharmaceutical industry expertise to Myovant. Most recently, Frank served as the Head of Commercial and Alliance Finance at Regeneron Pharmaceuticals (NASDAQ: REGN), where he supported a multifaceted business approaching $10 Billion in sales. Notably, Frank helped successfully launch multiple products globally and across several indications with Regeneron: Praluent (for hypercholesterolemia), Kevzara (for rheumatoid arthritis), Libtayo (for cutaneous squamous cell carcinoma), and Dupixent (for atopic dermatitis and asthma). Prior to joining Regeneron, Frank played a leading role in driving the finance organizations at Proteolix and at Onyx Pharmaceuticals (acquired by Onyx in 2009 and by Amgen in 2013, respectively). Frank earned his M.B.A. from the Wharton School at the University of Pennsylvania and holds a B.A. from the University of Washington.
Myovant Sciences (NYSE: MYOV) is a clinical stage biopharmaceutical company focused on redefining care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant’s team brings significant breadth and depth of expertise in drug development, combined with a commitment to develop new treatments for women suffering from uterine fibroids, endometriosis, and infertility, and for men suffering from prostate cancer. myovant.com
FlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards and CEOs to build successful, execution-focused management teams. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital. Learn more at flemingmartin.com